DK0545198T3 - Peptider med insulinagtig virkning - Google Patents

Peptider med insulinagtig virkning

Info

Publication number
DK0545198T3
DK0545198T3 DK92119913T DK92119913T DK0545198T3 DK 0545198 T3 DK0545198 T3 DK 0545198T3 DK 92119913 T DK92119913 T DK 92119913T DK 92119913 T DK92119913 T DK 92119913T DK 0545198 T3 DK0545198 T3 DK 0545198T3
Authority
DK
Denmark
Prior art keywords
residue
insulin
acid residue
alkyl
hydrogen atom
Prior art date
Application number
DK92119913T
Other languages
English (en)
Inventor
Stefan Dr Muellner
Wendelin Dr Frick
Guenter Dr Mueller
Gerhard Dr Breipohl
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0545198T3 publication Critical patent/DK0545198T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK92119913T 1991-11-29 1992-11-23 Peptider med insulinagtig virkning DK0545198T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4139376 1991-11-29

Publications (1)

Publication Number Publication Date
DK0545198T3 true DK0545198T3 (da) 2000-03-20

Family

ID=6445910

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92119913T DK0545198T3 (da) 1991-11-29 1992-11-23 Peptider med insulinagtig virkning

Country Status (11)

Country Link
US (1) US5622934A (da)
EP (1) EP0545198B1 (da)
JP (1) JP3324804B2 (da)
AT (1) ATE184611T1 (da)
DE (1) DE59209745D1 (da)
DK (1) DK0545198T3 (da)
ES (1) ES2137937T3 (da)
FI (1) FI925370A (da)
GR (1) GR3031850T3 (da)
NO (1) NO309146B1 (da)
SG (1) SG46640A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
KR100481746B1 (ko) * 1996-11-28 2005-08-10 훽스트 악티엔게젤샤프트 인슐린-유사작용을갖는이노시톨글리칸및이를포함하는약제학적제제
DE19649350A1 (de) * 1996-11-28 1998-06-04 Hoechst Ag Inositolglykane mit insulinartiger Wirkung
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
EP1836161B1 (en) 2004-12-22 2016-07-20 BHI Limited Partnership Methods and compositions for treating amyloid-related diseases
PL2089417T3 (pl) 2006-10-12 2015-07-31 Bhi Lp Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801175A1 (de) * 1978-01-12 1979-07-19 Hoechst Ag Verfahren zur herstellung cysteinhaltiger peptide
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
US4515920A (en) * 1984-04-30 1985-05-07 The Rockefeller University Synthesis of peptides and proteins
ES2039402T3 (es) * 1986-10-24 1993-10-01 Pfrimmer Kabi Gmbh & Co. Kg Empleo de peptidos n,n'-bis-l-aminoacido-l-cistina en preparados de aminoacidos para alimentacion oral y parenteral.
EP0288897B1 (de) * 1987-04-25 1993-08-11 Hoechst Aktiengesellschaft Enkastine: Neue Glycopeptide mit Enkephalinase-hemmender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als pharmazeutische Präparate
NZ232562A (en) * 1989-02-17 1992-10-28 Coselco Mimotopes Pty Ltd Immobilised peptide - solid support comprising a cleavable ester link between the peptide carboxy terminus and the solid support
US5214181A (en) * 1989-11-27 1993-05-25 Santen Pharmaceutical Co., Ltd. Amino acid derivatives
TW227004B (da) * 1990-12-19 1994-07-21 Hoechst Ag
YU66892A (sh) * 1991-08-20 1995-10-24 Hoechst Ag. Fosfoinositolglikan - peptid sa delovanjem kao insulin

Also Published As

Publication number Publication date
FI925370A (fi) 1993-05-30
DE59209745D1 (de) 1999-10-21
JPH05247088A (ja) 1993-09-24
ES2137937T3 (es) 2000-01-01
EP0545198A3 (da) 1994-03-23
NO924585D0 (no) 1992-11-27
EP0545198B1 (de) 1999-09-15
NO309146B1 (no) 2000-12-18
JP3324804B2 (ja) 2002-09-17
NO924585L (no) 1993-06-01
FI925370A0 (fi) 1992-11-26
GR3031850T3 (en) 2000-02-29
SG46640A1 (en) 1998-02-20
US5622934A (en) 1997-04-22
ATE184611T1 (de) 1999-10-15
EP0545198A2 (de) 1993-06-09

Similar Documents

Publication Publication Date Title
DE69210640T2 (de) Zahnmedizinische/medizinische Zusammensetzung für Restaurations-/Prothesenzwecke und ihre Verwendung
ATE196298T1 (de) Oberflächenaktives lungenprotein und verwandte polypeptide
AU564648B2 (en) Insulin agent
DE59209444D1 (de) 2-Phenylbenzo[b]furane und -thiophene, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
EP0434385A3 (en) Use of macrocyclic nitrogen containing compounds for the treatment of retroviral infections
DE69110101D1 (de) GIP-Analoge und deren Verwendung.
ES2190469T3 (es) Derivados de isocumarina y su uso en farmacos.
ES2071815T3 (es) Analogos de delecion de los peptidos conocidos como magaininas.
DK0545198T3 (da) Peptider med insulinagtig virkning
KR910700089A (ko) 히드로클로로플루오로프로판의 공비 조성물 또는 공비형 조성물
FI935318A (fi) 15-deoksispergualiinianalogit, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
KR890012929A (ko) 2개의 방향족 환 함유 화합물의 디아실화 방법
EP0328913A3 (de) Neue basisch substituierte 5-Halogen-Thienoisothiazol-3(2H)-on-1,1-dioxide, ein Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
ZA89431B (en) Oxadiazole compounds,their preparation and their use as pesticides
ATE102953T1 (de) Retro-inverso-thrymopentin-analoge, verfahren zu deren herstellung und deren verwendung fuer die zubereitung von pharmazeutischen zusammensetzungen.
ATE87939T1 (de) Glycosylierte aminosaeuren und peptide.
DE69017771D1 (de) Thymopentin-Analoge mit allen umgekehrten Verbindungen, Verfahren zur deren Herstellung und deren Verwendung zur Herstellung von pharmazeutischen Zusammensetzungen.